An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease’s progression compared to a placebo.

A new study sheds light on the risks and benefits of taking GLP-1 weight-loss drugs before having a baby.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! We’re closing in

Eli Lilly LLY briefly crossed the $1 trillion market cap on Nov. 21, 2025 — becoming the first-ever health-care company to join the elite group mainly

‘What if I told you that you can introduce foods into your diet that help the body increase its natural production of GLP-1? Foods you

NVO US Novo Nordisk A/S Sponsored ADR Class B BATS:NVO A3MInvestments The decline in Novo Nordisk shares is not the result of a single factor,

Novo and Lilly just slashed prices on GLP-1 weight-loss drugs that recently cost over $1,000 a month. What happened?

Good morning, Jason Mast here filling in for Ed. Happy turkey week to all. I, for one, have always detested that dry, tasteless bird. (It’s

Novo Nordisk’s shares fell 10% after the company said its oral semaglutide drug Rybelsus failed to meet the main goal in late-stage trials testing whether

For nearly two years Nicole Cowart’s doctor recommended she take a glucagon-like peptide-1 (GLP-1) receptor agonist. The doctor said it would help her manage her

Research highlights possible drawback of muscle mass loss through use of GLP-1 anti-obesity drugs

For the latest discoveries in cyber research for the week of 24th November, please download our Threat Intelligence Bulletin. Introduction to Malware Binary Triage (IMBT)

GLP-1 side effects  LAist Brain scientists are seeking weight-loss drugs without the nausea : Shots – Health News  NPR Brain activity associated with breakthrough food preoccupation in

GLP-1 receptor agonists are associated with a lower risk for serious infections, a recent meta-analysis suggests. Medscape Medical News

GLP-1 medicines, such as tirzepatide (Mounjaro) and semaglutide (Wegovy) work by making people feel fuller for longer

Novo Nordisk’s bet on semaglutide in Alzheimer’s disease was always a long shot, and like most long shots, it has missed the mark. The GLP-1

Two trials testing the Novo Nordisk weight loss drug semaglutide in Alzheimer’s disease failed, the company said Monday, showing the medicine did not slow the

UBS has initiated coverage of Shaily Engineering Plastics with a ‘Buy’ rating and a target price of ₹4,000, indicating a 60% upside. The firm highlights

The Trump administration’s new deal lowers prices and expands access to GLP-1 drugs, but experts argue far broader reforms are needed to address high prescription

In addition to reducing hunger, popular weight-loss drugs also affect reward processing and motivated behaviors. New research is offering a clearer picture of how medications

The new drug will target weight loss for people with obesity and type 2 diabetes.

A new oral GLP-1 medication can help adults with obesity and type 2 diabetes lose more weight and improve their blood sugar levels compared to

Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1  Seeking Alpha High-stakes Novo Nordisk Alzheimer’s studies could yield answers on GLP-1 benefit  Reuters Can GLP-1 drugs

Post Content

A Consolidated Overview Continue reading on Penny Press »

Over the past several years, GLP-1 agonist weight-loss drugs have evolved from a celebrity trend to arguably the hottest growth opportunity in the pharmaceutical industry.

Biology, Vol. 14, Pages 1650: GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects Biology doi:

Nutrients, Vol. 17, Pages 3659: Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery? Nutrients doi:

Eli Lilly Hits $1 Trillion Milestone on GLP-1 Boom Eli Lilly and Company BATS:LLY DEXWireNews Eli Lilly & Co. (NYSE: LLY ) briefly crossed the

The Ozempic era should change how we think about self-control Oh, oh, oh, Ozempic! The catchy jingle from Novo Nordisk’s 2018 TV commercial helped to

Post Content

Eli Lilly becomes first pharma firm to join $1 trillion club  Al Jazeera Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value  The

The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with pharmaceutical giants, announced Nov. 6, 2025,

Eli Lilly Tops $1 Trillion, Joins Tech Titans In Exclusive Club  Investor’s Business Daily Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in

Revising our earlier interpretation of SELECT trial data in light of new analyses The post Cardiovascular benefits of GLP-1 drugs independent of weight loss appeared

ABSTRACT There are large evidence gaps for pregnant people, and research in pregnancy should be prioritized to ensure strong evidence to guide safe clinical practice.

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and

Eli Lilly reached a $1 trillion market capitalization on Friday, the first health-care company in the world to join the exclusive club dominated by tech

A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular protection—reducing heart attack, stroke, and death in adults with type